Literature DB >> 1620551

Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination.

W R Taylor1, S E Egan, M Mowat, A H Greenberg, J A Wright.   

Abstract

Mouse 10T1/2 cells were transfected with combinations of T24 H-ras, human c-myc and the proline 193 mutant form of p53. The three-gene ras/myc/p53 combination was significantly more efficient than single genes or double gene combinations in inducing transformed foci in vitro. An analysis of cell lines isolated after transfections with ras, ras/myc, ras/p53 and ras/myc/p53 indicated that the last combination contained significantly higher levels of ras protein than the other combinations, produced tumors in syngeneic mice with a shorter latency period, and exhibited an increased ability to form lung tumors in an in vivo experimental metastasis assay. Synergistic interactions between ras, myc and mutant p53 genes were observed in focus formation and metastasis assays, suggesting that the action of the three oncogenes in malignant transformation occurs along separate but interactive pathways. These results support a working model of oncogene cooperativity in which alterations in myc and p53 permit elevated expression of ras, which is important in a mechanism affecting both cellular transformation in vitro and tumor dissemination in vivo.

Entities:  

Mesh:

Year:  1992        PMID: 1620551

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  A free-radical hypothesis for the instability and evolution of genotype and phenotype in vitro.

Authors:  R E Parchment; K Natarajan
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

2.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.

Authors:  H Fan; A Huang; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

4.  Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.

Authors:  R E Jimenez; A L Warshaw; K Z'graggen; W Hartwig; D Z Taylor; C C Compton; C Fernández-del Castillo
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

5.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.

Authors:  H Fan; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

Authors:  Catherine A Vaughan; Rebecca Frum; Isabella Pearsall; Shilpa Singh; Brad Windle; Andrew Yeudall; Swati P Deb; Sumitra Deb
Journal:  Biochem Biophys Res Commun       Date:  2012-09-16       Impact factor: 3.575

7.  Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.

Authors:  Józefa Węsierska-Gądek; Eva Walzi; Iva Dolečkova; Gerald Schmid
Journal:  Cancer Microenviron       Date:  2009-09-04

8.  Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Authors:  Catherine A Vaughan; Shilpa Singh; Brad Windle; W Andrew Yeudall; Rebecca Frum; Steven R Grossman; Swati P Deb; Sumitra Deb
Journal:  Genes Cancer       Date:  2012-07

9.  Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.

Authors:  V C Padmakumar; Eiman Aleem; Cyril Berthet; Mary Beth Hilton; Philipp Kaldis
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

10.  Mutation of the endogenous p53 gene in cells transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism.

Authors:  J W Peacock; S Benchimol
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.